良性前列腺增生门诊患者治疗用药研究  

Study on Diagnosis and Treatment of Benign Prostatic Hyperplasia Outpatients in Department of Geriatrics in China

作　　者：吴楠 孙健 张秋桂 孙振球[3] 

机构地区：[1]广东深圳南山区疾病预防控制中心,广东深圳518054 [2]江西万载县疾病预防控制中心,江西万载336100 [3]湖南长沙市中南大学医学院,湖南长沙410078

出　　处：《中国医药指南》2011年第33期9-10,共2页Guide of China Medicine

摘　　要：目的了解中国老年科医师对良性前列腺增生门诊患者用药情况。方法采用横断面调查的方法,对中国11个城市33个三级甲等医院老年科医师对BPH患者用药情况调查。结果在单用药物治疗中,北方城市5-α还原酶抑制剂单用采用率(28.2%)大于南方城市(22.4%);但α-受体阻滞剂(8.1%)和中药植物制剂(5.4%)低于南方城市α-受体阻滞剂(16.4%)和中药植物制剂(7.9%)。在联合药物治疗中,北方城市α-受体阻滞剂和5-α还原酶抑制剂联合采用率(55.0%)大于南方城市(41.6%);但中药植物制剂与α-受体阻滞剂或5-α还原酶抑制剂联合采用率(3.3%)小于南方城市(11.7%)。随着患者症状严重程度的增加,α-受体阻滞剂和5-α还原酶抑制剂联合采用率也增大。结论本研究对BPH患者用药情况进行了调查。研究结果可能会为BPH诊疗提供参考。Objective The goal of this study was to assess BPH drugs preferences of doctors.Methods This cross-sectional study was performed in 33 medical centers located in 11 different cities in china.A survey investigated doctors who were asked to record their preferences in drugs for elderly BPH cases.Results The rate of use for 5-α reductase inhibitor monotherapy in the north（28.2%） was higher than that in the south（22.4%）;the rates of use for α-adrenoceptor antagonist monotherapy and plant monotherapy in the north（8.1% and 5.4%） was lower than those in the south（16.4% and 7.9%）.The rate of use for combination therapy with α-adrenoceptor antagonist and 5α-reductase inhibitor in the north（55.0%） was higher than that in the south（41.6%）,while the rate of use for combination therapy with plant and α-adrenoceptor antagonist or 5-α reductase inhibitor in the north（3.3%） was lower than that in the south（11.7%）.The rate of use for combination therapy with α-adrenoceptor antagonist and 5α-reductase inhibitor was increasing with the severity of symptoms.Conclusions This study provides insight into the preferences of doctors regarding drug.The study may also provides reference for the china BPH clinical practice.

关 键 词：良性前列腺增生 5-Α还原酶抑制剂 Α-受体阻滞剂 中药植物制剂 

分 类 号：R697.3[医药卫生—泌尿科学]